This lesson follows that case from the law that started it to its position in November 2026: what the rule required, why the industry objected, how the courts ruled, how a premium cigar is now defined, and what remains open. Regulation and Legal — USA, EU, Russia sets out how American, European and Russian rules compare; Boutique and Newer Brands describes how small makers lived through the rule; and Global Market Trends covers the American market, its taxes and the tariffs of 2025 and 2026. Most of the cigars at stake are rolled in Nicaragua, the Dominican Republic and Honduras for American smokers, and the two Economic Impact lessons show how much those countries depend on that market. Cuban cigars, which the embargo keeps out of the United States, play no part in the case.
The 2009 law and the power to deem
The Family Smoking Prevention and Tobacco Control Act, signed in June 2009, gave the Food and Drug Administration (FDA) power over tobacco for the first time. The law applied at once to cigarettes, cigarette tobacco, roll-your-own tobacco and smokeless tobacco. Cigars were not on the list. Instead, the law let the FDA bring any other tobacco product under the same rules by regulation, a step it called "deeming": the agency declares that a product is subject to the law, and from then on it is treated much as a cigarette is.
A product under the law faces a long list of duties. Its maker must register with the FDA, list its products and report their ingredients. It may not be sold to minors, given away as a free sample or sold from most vending machines. It must carry the required health warnings. Above all, a "new" product needs the agency's permission before it can be sold, and the makers of each class of product pay their share of the FDA's tobacco budget through user fees. The law did allow the FDA to restrict tobacco, but it did not allow the agency to ban cigarettes or any other class of tobacco product outright.
The predicate date and the two roads to market
The law drew its line between old and new products at 15 February 2007, the day the bill that became the law was introduced in Congress. A product sold in the United States on that date is "grandfathered": it may stay on sale without review. In the language of the law, it can also serve as a "predicate", the existing product a new one is compared with, which is why 15 February 2007 is often called the predicate date. Any product introduced after that date, or changed after it, counts as new. Congress, not the FDA, chose the date, and in later rounds of the case the courts held that the agency had no power to move it.
A new product can reach the market in two main ways. The first is a report of substantial equivalence: the maker shows that the new product has the same characteristics as a grandfathered predicate, or that its differences raise no new questions of public health. The second is a premarket tobacco product application, known by its initials as a PMTA, in which the maker must show that selling the product would be appropriate for the protection of public health, a far heavier task. A minor change, such as adjusting an additive, can be handled by a request for exemption. The agency's own analysis of the deeming rule estimated about 300 hours of work for a full equivalence report, including the environmental assessment that must go with it, and expected that no premium cigar would try the PMTA route at all.
The deeming rule and the option not taken
The FDA published its proposal in April 2014 and offered two choices. "Option 1" would deem every tobacco product not yet covered, cigars of every kind included. "Option 2" was the same except that it left out premium cigars, which it defined by eight features: a wrapper of whole tobacco leaf, a binder of 100 percent leaf tobacco, mainly long filler, the wrapper, binder and filler joined by hand, no filter, tip or non-tobacco mouthpiece and a head capped by hand, a retail price of at least $10 a cigar, no characterising flavour other than tobacco, and a weight of more than 6 pounds per 1,000 cigars. The agency explained that different kinds of cigar might have different effects on public health and asked for evidence.
The industry and its associations backed Option 2. They pointed to two studies in particular. A 2014 report from the Centers for Disease Control and Prevention, drawn from a national survey of 60,192 adults in 2012 and 2013, found that only 3.3 percent of premium cigar smokers smoked one every day, while 25.6 percent smoked on some days and 71.2 percent rarely. A 1998 review by the National Cancer Institute had found no statistically significant difference in deaths from all causes between people who had never smoked and those who smoked no more than two cigars a day.
The final rule, published on 10 May 2016 and in force from 8 August 2016, chose Option 1. It deemed cigars, pipe tobacco, electronic cigarettes, hookah tobacco and other products, with no exception for premium cigars. The FDA gave three reasons: all cigars carry serious health risks, the evidence did not support a separate treatment for premium cigars, and young people smoke them too. It also wrote that commenters had submitted no data showing that the way premium cigars are smoked reduces their health risks. That sentence later decided the case.
What the rule required of cigar makers
Under the rule, a cigar sold on 15 February 2007 was grandfathered. A cigar introduced between that date and 8 August 2016 could stay on sale for the time being, but its maker had to file an equivalence report within 18 months, by February 2018, or a PMTA within 24 months. A cigar introduced after 8 August 2016 could not be sold at all until the FDA had authorised it. For an industry that brings out new blends, sizes and limited editions every year, this was the heart of the matter. In the rulemaking, trade comments estimated that 10,000 to 20,000 different cigar products were sold in the United States and that a typical premium maker offered more than 100 of them, replacing about 15 percent each year. Makers also argued that, because no two harvests are alike, even a blend sold since before 2007 changes slightly from year to year and might count as new. The FDA itself assumed that about 60 percent of cigar products would turn out to be grandfathered.
The rule also brought health warnings. Every cigar package had to carry one of six warnings in rotation, covering at least 30 percent of its two main panels, and the same warnings had to take up 20 percent of every advertisement; cigars sold singly were to be covered by a sign at the counter. Five of the six repeated warnings that the largest cigar makers had agreed with the Federal Trade Commission in 2000. The warnings were due to start in August 2018.
Finally, cigar makers and importers began paying user fees. The total that the FDA may collect each year is set by law and divided among six classes of tobacco product according to their share of federal excise tax; within the cigar class each company pays according to its own share. Because the federal excise tax on a large cigar is capped, as the section on tax explains below, a premium cigar's share is set largely by the number of cigars sold rather than by their price.
The lawsuit and its first rounds
On 15 July 2016 the industry went to court in Cigar Association of America v. FDA, in the federal District Court for the District of Columbia. The case was heard by Judge Amit Mehta. Three associations brought it: the Cigar Association of America (CAA), which speaks mainly for manufacturers and importers, including the large makers of machine-made cigars; Cigar Rights of America (CRA), which represents smokers and premium makers; and the retailers' association then called the International Premium Cigar and Pipe Retailers Association, which renamed itself the Premium Cigar Association (PCA) in 2019. They challenged the rule on many grounds, but their central claim relied on the Administrative Procedure Act, the federal law on how agencies must make rules. That law requires a court to set aside agency action that is "arbitrary and capricious", which in plain terms means a decision the agency has not reasonably explained, for example because it ignored relevant evidence put before it.
The case moved slowly because the rule itself kept changing. In 2017 the new leadership of the FDA delayed the deadlines, first by three months in May and then, in a plan announced in July and set out in guidance in August, until 8 August 2021 for applications covering cigars and other combustible products. The industry narrowed its suit in response. Public-health groups challenged the delay in a separate case in a federal court in Maryland, which in 2019 struck down the guidance and ordered applications within ten months; because of the pandemic the deadline was later moved to 9 September 2020.
The rulings in the District of Columbia went both ways. On 15 May 2018 Judge Mehta upheld most of the rule: the warnings did not violate the First Amendment or the tobacco law, and the user fees were lawful. He then put the warnings on hold while the industry appealed. On 3 February 2020 he set aside the warning requirement for premium cigars, finding that the FDA had not explained why they should carry the same warnings as mass-market cigars. On 7 July 2020 the Court of Appeals for the District of Columbia Circuit, deciding the industry's appeal of the 2018 ruling, went further: the law required the FDA to consider whether its warnings would change the number of people using tobacco, and the agency had not done so. In September 2020 the district court vacated the warning requirements for all cigars and pipe tobacco. To "vacate" a rule is to annul it, so that it no longer has legal effect. The FDA has not proposed new cigar warnings since.
On 19 August 2020 Judge Mehta ruled on the premarket requirements. He rejected most of the industry's arguments, among them a challenge to the predicate date, but he found that the FDA had not properly answered comments asking for a simpler review process for premium cigars. He sent that question back to the agency and barred it from enforcing premarket review against premium cigars until it had done so. For that ruling he used a definition of premium cigar that the FDA had placed in a draft guidance only weeks earlier, on 5 August 2020, in the Maryland case; the agency withdrew the draft later that month. On 20 July 2021 the appeals court upheld the district court on the premarket, equivalence and predicate-date questions, so on those points the industry lost.
Meanwhile the FDA kept studying the subject. In March 2018 it asked the public for data on premium cigars in an advance notice of proposed rulemaking, an early step that seeks information before a rule is drafted. It then asked the National Academies of Sciences, Engineering, and Medicine to review the evidence, and in 2021 set the notice aside to await the result.
The 2022 and 2023 rulings
On 5 July 2022 Judge Mehta ruled on the claim at the centre of the case. He found that the FDA had acted arbitrarily and capriciously in refusing to exempt premium cigars. The agency had summarised the two studies in its record but had never engaged with what they showed, and it had then said in absolute terms that no such evidence existed. He called that reasoning nonresponsive and circular. He did not decide the remedy at once and asked the parties to argue it.
The remedy came on 9 August 2023. The FDA asked for "remand without vacatur", meaning that the rule would stay in force while the agency reconsidered it. The judge refused and vacated the deeming rule "insofar as it applies to premium cigars". He found the agency's error serious, thought it possible that the FDA would decide differently on reconsideration, and judged that annulling the rule for this narrow category would cause little disruption. For the boundary of that category he again used the eight-part definition from the FDA's August 2020 draft guidance. From that day the federal requirements that came with the deeming rule, including registration and product listing, ingredient reporting, premarket review and user fees, ceased to apply to cigars that meet the definition. Every other cigar remained under the rule.
The appeal and the definition
The government appealed in October 2023. The appeals court heard argument on 13 September 2024 and gave its decision on 24 January 2025, in an opinion by Senior Judge A. Raymond Randolph for a panel of three. It agreed with Judge Mehta that the rule was arbitrary and capricious for premium cigars, for two reasons: the FDA's explanation rested on a false statement of fact, that no evidence had been submitted, and the agency had failed to examine data that went to the central question its own proposal had asked. The court called the case "a textbook example" of an agency not responding to such data, and it upheld the choice to vacate rather than merely remand. It added two limits. The relief applies only from the date of the 2023 order onward, so it does not require the FDA to refund user fees already paid. And because the FDA had never formally adopted the eight-part definition, which differed in several ways from its 2014 proposal, the court sent the case back, a step called a "remand", so that the district court could hear the parties on the definition before entering a final order. The court noted that the FDA remained free to begin a new rulemaking to define premium cigars or to regulate them again. On 26 March 2025, on a request for rehearing, the court reissued the opinion with amended wording, "affirmed in part, reversed in part, and remanded", which made clear that the vacatur itself stood.
On remand the three associations divided. The CRA and the PCA asked the court to keep the existing definition, and so did the FDA, which said it had applied that definition in practice for years, including in its handling of user fees, and that any change should come through the agency's own rulemaking. The CAA, whose members include makers of flavoured and machine-made cigars, filed a broader definition on 6 June 2025. It had five parts instead of eight and left out the bar on characterising flavours, and it would have admitted some cigars made with the help of machines.
On 15 April 2026 Judge Mehta re-adopted the definition without change. He pointed to the years in which the FDA and the industry had relied on it, said that the court lacked the agency's expertise to judge the public-health effects of the changes the CAA proposed, and left any refinement to rulemaking. Under that order, a premium cigar is a cigar that meets all eight of the following tests.
- It is wrapped in whole tobacco leaf.
- It has a binder of 100 percent leaf tobacco.
- At least 50 percent of its filler, by weight, is long-filler tobacco.
- It is handmade or hand-rolled.
- It has no filter, non-tobacco tip or non-tobacco mouthpiece.
- It has no characterising flavour other than tobacco.
- It contains only tobacco, water and vegetable gum, with no other ingredients or additives.
- It weighs more than 6 pounds per 1,000 cigars.
Long filler is filler made of whole or half leaves running the length of the cigar, as opposed to short filler, chopped leaf. A characterising flavour is a taste or aroma other than tobacco, such as vanilla, cherry or menthol, that is noticeable in the product or its smoke. Compared with the FDA's 2014 version, the court's definition drops the $10 price test, adds the rule on ingredients, measures the long filler by weight and replaces "capped by hand" with the simpler "handmade or hand-rolled". A flavoured or infused cigar fails the sixth test even when it is rolled by hand, and a machine-bunched cigar fails the fourth, so both remain under the FDA's rule.
Where the case stands in November 2026
The April 2026 order is the law that applies today. Cigars that meet all eight tests are outside the deeming rule, and the FDA's own notices to cigar companies, the latest for the fourth quarter of its 2026 fiscal year, quote the definition and say that the agency does not intend to charge user fees on them. Its proposals of 2025 and 2026, described below, leave premium cigars out in the same way. No appeal of the April order had been reported by November 2026. Sources do not quite agree on whether the case is closed: a feature published in August 2026 said that the CAA could still appeal and had not decided, while a proposed rule the FDA published on 29 June 2026 still described the litigation as pending.
Three questions remain open. The first is the old user fees. The government estimated in a 2024 court filing that the fees paid on premium cigars between 2016 and 2023 came to more than $100 million, and the FDA has said it will not refund fees for the period before the 2023 order. In July 2026 nine makers, Arturo Fuente, Ashton, CLE Cigar, J.C. Newman, La Flor Dominicana, My Father Cigars, Oliva, Padrón and Rocky Patel, sued the United States in the Court of Federal Claims, the court that hears money claims against the federal government, for at least $10 million in fees plus interest. That case is pending. The second is how the FDA will share out the fees that premium cigars no longer pay; the agency has said it is considering options but cannot yet separate premium cigars from other cigars in the excise data it uses. The third, and the largest, is that the exemption rests on a court order, not on a statute. The FDA may begin a new rulemaking and, if it answers the evidence it ignored in 2016, bring premium cigars back under its authority. As of November 2026 it had not proposed to do so.
Flavours, nicotine and foreign factories
Other federal proposals have touched cigars, and premium cigars have usually been left out of them. On 4 May 2022 the FDA published proposed product standards that would have banned menthol in cigarettes and every characterising flavour other than tobacco in all cigars, premium ones included. The new administration withdrew both proposals on 21 January 2025; reports of the withdrawal give dates between 21 and 27 January. On 16 January 2025 the FDA proposed to cap the nicotine in cigarettes and some other smoked tobacco at 0.70 milligrams per gram of tobacco; that proposal covers little cigars, cigarillos and large cigars but excludes premium cigars, and it had not become a final rule by November 2026. On 29 June 2026 the agency proposed to make foreign factories register with it and list the tobacco products they ship to the United States, which would reach many factories in the Caribbean and Central America; the proposal states that it would not apply to premium cigars outside the FDA's authority. Its comment period closed on 14 September 2026.
The federal excise tax
Excise tax is separate from FDA regulation. It is collected by the Treasury's Alcohol and Tobacco Tax and Trade Bureau, and the deeming case did not affect it. Since 1 April 2009 a large cigar, one weighing more than 3 pounds per 1,000, has been taxed at 52.75 percent of the price for which the manufacturer or importer sells it, but never more than 40.26 cents a cigar. The cap means that a cigar the importer sells for about 76 cents or more pays the same 40.26 cents, so almost every premium cigar pays the flat cap rather than the percentage. Small cigars pay $50.33 per 1,000. Tariffs, the duties charged at the border, are another matter again; those imposed on Nicaraguan, Dominican and Honduran goods in 2025 and 2026 are described in Global Market Trends.
Bills in Congress
Congress has been asked many times to settle the question by statute. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act would exempt traditional large and premium cigars from FDA regulation. It was first introduced in 2011, when the House version gathered more than 200 cosponsors, and has been reintroduced in most Congresses since, most recently in the Senate on 25 February 2026, where it was referred to the Committee on Health, Education, Labor, and Pensions. In the House, a bill introduced on 14 March 2025 (H.R. 2111) would also exempt premium cigars; it was referred to the Committee on Energy and Commerce. None of these bills had reached a vote in either chamber by November 2026, and none has become law.
The states
The federal case does not limit the states, which set their own minimum ages, taxes and flavour laws. California's ban on flavoured tobacco, which voters upheld in a referendum on 8 November 2022, uses its own, different definition of a premium cigar, based on handmade construction, a whole-leaf wrapper and a wholesale price of at least $12, and exempts such cigars only in limited settings. On 27 August 2026 the federal appeals court for the Ninth Circuit upheld California's list of approved unflavoured tobacco products against a challenge led by Rocky Patel Premium Cigars, finding that the federal tobacco law does not override it.
The two positions
Public-health groups and the FDA argued that every cigar is harmful and addictive, that no level of use is safe and that one rule should cover all tobacco. The industry argued that premium cigars are smoked rarely, mostly by adults, and are sold mainly in specialist shops. The scientific review the FDA commissioned, published by the National Academies in 2022, found evidence for parts of both views. About 0.7 percent of American adults had smoked a premium cigar in the past 30 days in 2013 and 2014, and those who did smoked on a median of 1.7 days a month. Yet the reviewers found no material difference in the harmful constituents of premium and other cigar smoke, linked regular cigar smoking in general with heart disease and cancers of the mouth, oesophagus, larynx and lung, and noted that there was no single accepted definition of a premium cigar. The courts did not decide this health debate. They held that the FDA, having asked whether premium cigars should be treated differently, had to answer the evidence it received, and it had not.
What the rule meant for makers
For the small companies that make up most of the premium trade, the rule was a question of survival. The cost of an equivalence report was modest for one product but multiplied across a catalogue of dozens of blends and sizes, and every new size or band could count as a new product. Makers responded by rushing releases onto the market before 8 August 2016, by keeping blends sold before 2007 because they needed no review, and by holding back new ones; Boutique and Newer Brands describes how several small brands did this. The 2020 injunction and the 2023 vacatur removed that pressure for cigars that meet the definition, and the exemption now shapes how cigars are made, since a maker who adds a flavour or bunches the filler by machine brings the product back under the FDA. The cigars affected are largely made abroad: in 2025 Nicaragua, the Dominican Republic and Honduras supplied almost all the premium cigars imported into the United States, as Global Market Trends shows, so a federal rule on American shelves reaches factories in Estelí, Santiago and Danlí.
The timeline
The table puts the main steps of the case in order, with the effect of each on premium cigars. Read down the third column and the pattern is clear: the industry lost most of its early arguments about deadlines, fees and the predicate date, and won on the one point where the FDA's own record contradicted it.
| Date | Event | Effect on premium cigars |
|---|---|---|
| 22 June 2009 | Tobacco Control Act signed | FDA gains power over tobacco; cigars not yet covered |
| 25 April 2014 | Deeming rule proposed with Option 1 and Option 2 | Option 2 would have exempted premium cigars |
| 10 May 2016 | Final deeming rule published; in force 8 August 2016 | All cigars covered; post-2007 cigars need FDA review |
| 15 July 2016 | Cigar Association of America v. FDA filed | Industry challenges the rule |
| August 2017 | FDA guidance delays deadlines to 2021 | Applications postponed; later struck down by a Maryland court |
| 15 May 2018 | District court upholds warnings and user fees | Fees continue; warnings put on hold for the appeal |
| 7 July 2020 | Appeals court rules against the cigar warnings | Warnings vacated for all cigars in September 2020 |
| 19 August 2020 | Premarket review barred for premium cigars | FDA may not enforce premarket review against premium cigars |
| 5 July 2022 | FDA found to have acted arbitrarily and capriciously | Liability decided; remedy left open |
| 9 August 2023 | Rule vacated insofar as it applies to premium cigars | User fees, premarket review and other duties end for premium cigars |
| 24 January 2025 | Appeals court upholds the vacatur, remands the definition | Exemption stands; no refunds of past fees |
| 15 April 2026 | Eight-part definition re-adopted | Flavoured and machine-made cigars stay under FDA rules |
| July 2026 | Nine makers sue for refunds of past user fees | Pending |
